PrairieView Partners’s TherapeuticsMD TXMD Stock Holding History

PrairieView Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	486
2022 Q1	$0	Buy	+1	New	+$16	﹤0.01%	486

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

PrairieView Partners's TXMD Position: Q2 2022 in Review

PrairieView Partners sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1 share.

PrairieView Partners first reported a position in TXMD in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

PrairieView Partners reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
PrairieView Partners sold 1 TherapeuticsMD share in Q2 2022.
PrairieView Partners first reported a position in TherapeuticsMD in Q1 2022 and held it in 1 quarter.
PrairieView Partners's TherapeuticsMD position peaked at $0 in Q1 2022.
53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on PrairieView Partners's 13F filing for Q2 2022, filed 22 Jul 2022.